Activity of IAP antagonist Debio 1143 as a monotherapy and in combination with standard of care agents in models of human lung cancer of different histotypes

N. Wiedemann (1), C.G. Langdon (2), M.A. Held (2), J.T. Platt(2), F. Lévy (1), D. Robichon (1), C. Zanna (1), G. Vuagniaux (1), M. Sorensen (3), S. Wang (4), M.W. Bosenberg (2), D.F. Stern (2).

Presented at ELCC 2014, Geneva, Switzerland

(1) Debiopharm International SA, Switzerland

(2) Yale University, USA

(3) Ascenta Therapeutics, USA

(4) University of Michigan Cancer Center, USA